View of 52-Week Safety and Efficacy of Amlitelimab in Participants with Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis from the Open-Label Long-Term ATLANTIS Trial

Return to Article Details 52-Week Safety and Efficacy of Amlitelimab in Participants with Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis from the Open-Label Long-Term ATLANTIS Trial Download Download PDF